Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Total Valuation
Dr Reddy's Laboratories has a market cap or net worth of $10.76B. The enterprise value is $13.12B.
Market Cap$10.76B
Enterprise Value$13.12B
Share Statistics
Dr Reddy's Laboratories has 834.42M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding834.42M
Owned by Insiders
Owned by Instutions3.78%
Financial Efficiency
Dr Reddy's Laboratories’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 17.18%.
Return on Equity (ROE)19.85%
Return on Assets (ROA)14.37%
Return on Invested Capital (ROIC)17.18%
Return on Capital Employed (ROCE)23.24%
Revenue Per Employee$11,509,353.741
Profits Per Employee$1,984,472.05
Employee Count27,048
Asset Turnover0.72
Inventory Turnover1.82
Valuation Ratios
The current PE Ratio of Dr Reddy's Laboratories is 18.45. Dr Reddy's Laboratories’s PEG ratio is 0.80.
PE Ratio18.45
PS Ratio3.68
PB Ratio3.66
Price to Fair Value3.66
Price to FCF57.09
Price to Operating Cash Flow22.61
PEG Ratio0.80
Income Statement
In the last 12 months, Dr Reddy's Laboratories had revenue of $311.31B and earned $53.68B in profits. Earnings per share was $64.41.
Revenue$311.31B
Gross Profit$184.65B
Operating Income$68.98B
Pretax Income$72.75B
Net Income$53.68B
EBITDA88.43B
Earnings Per Share (EPS)64.41
Cash Flow
In the last 12 months, operating cash flow was $35.95B and capital expenditures -$29.43B, giving a free cash flow of $6.52B billion.
Operating Cash Flow$35.95B
Free Cash Flow$6.52B
Free Cash Flow per Share$7.81
Dividends & Yields
Dr Reddy's Laboratories pays an annual dividend of $0.08, resulting in a dividend yield of 0.61%
Dividend Per Share$0.08
Dividend Yield0.61%
Payout Ratio10.63%
Free Cash Flow Yield1.75%
Earnings Yield5.42%
Stock Price Statistics
Beta0.42
52-Week Price Change-6.57%
50-Day Moving Average13.24
200-Day Moving Average14.89
Relative Strength Index (RSI)52.16
Average Volume (3m)2.19M
Important Dates
Dr Reddy's Laboratories upcoming earnings date is May 9, 2025, Before Open.
Last Earnings DateJan 23, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend DateJul 30, 2024
Financial Position
Dr Reddy's Laboratories as a current ratio of 2.58, with Debt / Equity ratio of 0.07
Current Ratio2.58
Quick Ratio1.92
Debt to Market Cap0.02
Net Debt to EBITDA0.15
Interest Coverage Ratio39.58
Taxes
In the past 12 months, Dr Reddy's Laboratories has paid $18.30B in taxes.
Income Tax$18.30B
Effective Tax Rate22.52%
Enterprise Valuation
Dr Reddy's Laboratories EV to EBITDA ratio is 11.77, with an EV/FCF ratio of 57.80.
EV to Sales3.73
EV to EBITDA11.77
EV to Free Cash Flow57.80
EV to Operating Cash Flow22.90
Balance Sheet
Dr Reddy's Laboratories has $59.18B in cash and marketable securities with $51.09B in debt, giving a net cash position of -$8.09B billion.
Cash & Marketable Securities$59.18B
Total Debt$51.09B
Net Cash-$8.09B
Net Cash Per Share-$9.70
Tangible Book Value Per Share$287.14
Margins
Gross margin is 58.61%, with operating margin of 24.26%, and net profit margin of 19.95%.
Gross Margin58.61%
Operating Margin24.26%
Pretax Margin25.74%
Net Profit Margin19.95%
EBITDA Margin31.67%
EBIT Margin26.36%
Analyst Forecast
The average price target for Dr Reddy's Laboratories is $18.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.20
Price Target Upside37.67%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast13.26%
EPS Growth Forecast1.33%